A Beginner's Guide to Peptides: Biochemistry, Classes, and the Research Landscape

1. Peptide Basics: What This Guide Covers

In short: peptides are short amino acid chains that include some of the most successful drugs of the last decade (like Ozempic) alongside a much larger group of compounds with weaker evidence and no regulatory approval. Peptides occupy a peculiar middle zone of pharmacology. They are too large to be classified as small-molecule drugs and too small to be called proteins, and the two most successful recent drug launches in the category, semaglutide and tirzepatide, have made "peptide" one of the most searched health terms of the decade [1,2].

Most compounds discussed under the peptide label, however, are not approved for human therapeutic use and sit in a research-chemical or compounding-pharmacy gray zone that confuses new readers quickly. This guide is written for readers who want a technically honest orientation to what peptides are, how they are classified, how the literature describes them, and how to read that literature without being led astray by vendor marketing.

2. What Peptides Actually Are

In short: a peptide is a chain of amino acids — longer than a tiny molecule like ibuprofen but shorter than a full protein like antibodies or enzymes. A peptide is a short chain of amino acids joined by peptide bonds. The operational definition used by most pharmacology references is a chain of roughly two to fifty amino acid residues, though the upper boundary blurs where peptides become proteins and the lower boundary blurs where peptides become small-molecule dipeptides [3]. Insulin, at 51 amino acids, is conventionally classified as a small protein despite often being described colloquially as a peptide hormone. Semaglutide, at 31 amino acids with a fatty acid modification, is unambiguously a peptide. BPC-157, at 15 amino acids, sits comfortably in the category.

The distinction between peptides and small molecules is not merely size. Small molecules such as ibuprofen or atorvastatin typically weigh under 900 daltons, are orally bioavailable after metabolic processing in the liver, and interact with their targets through rigid chemical scaffolds. Peptides weigh from several hundred to several thousand daltons, are generally degraded in the gastrointestinal tract unless chemically modified or encapsulated, and engage their targets through flexible backbone conformations that can mimic endogenous signaling molecules [3]. This is why the route of administration for most therapeutic peptides is subcutaneous or intravenous rather than oral. Oral semaglutide (Rybelsus) exists as an engineered exception that pairs the molecule with a permeation enhancer, not as the rule.

The distinction between peptides and proteins is a convention of length and function. A protein typically has tertiary structure, meaning it folds into a reproducible three-dimensional shape stabilized by hydrogen bonding and disulfide bridges. A short peptide may adopt transient secondary structures in solution but rarely folds into a stable tertiary form. This has consequences for how these molecules are manufactured, stored, and dosed. Solid-phase peptide synthesis, introduced by Merrifield in the 1960s, is the standard manufacturing method for short synthetic peptides, while proteins are typically produced by recombinant expression in bacterial, yeast, or mammalian cell culture [4].

3. How the Literature Classifies Peptides

In short: peptides are grouped by what they do — GLP-1 agonists for weight loss and diabetes, growth-hormone secretagogues for body composition, healing peptides for tissue repair, and so on. Peptide research is fragmented across many therapeutic categories. The categories below are the ones a reader will encounter most often when browsing PubMed, ClinicalTrials.gov, or the peptide-research community.

Growth-hormone secretagogues. This class includes growth-hormone-releasing-hormone (GHRH) analogues such as sermorelin, CJC-1295, and tesamorelin, along with ghrelin-receptor agonists known as growth-hormone-releasing peptides (GHRPs), including ipamorelin, GHRP-2, GHRP-6, and hexarelin. These compounds stimulate endogenous growth hormone release from the pituitary rather than replacing growth hormone directly [5]. Only tesamorelin carries FDA approval, for a narrow indication of HIV-associated lipodystrophy.

GLP-1 and dual incretin agonists. Semaglutide, liraglutide, dulaglutide, and tirzepatide are the marquee examples. These molecules engage glucagon-like-peptide-1 receptors and, in the case of tirzepatide and retatrutide, additional incretin receptors (GIP, glucagon). They have approved indications for type 2 diabetes and, in several cases, chronic weight management [1,2]. This is the category where peptide therapeutics have achieved the greatest commercial and clinical traction.

Healing and tissue-repair peptides. BPC-157 and TB-500 (thymosin beta-4 fragment) are the most discussed, along with pentadeca arginate and LL-37. None of these are approved for human therapeutic use. The published data are overwhelmingly preclinical, and most of the commentary treats animal efficacy as if it translated directly to human benefit, which it rarely does.

Bioregulators. Short peptides associated with Russian research programs, including Epitalon, Thymalin, and several others. The claims associated with this category (longevity, circadian modulation, thymic function) rest on a distinctive research tradition whose methodology and replication standards differ from Western clinical trial norms.

Nootropic peptides. Selank, Semax, Noopept, Cerebrolysin, and Dihexa are the compounds most often discussed. Clinical and preclinical evidence varies substantially. Cerebrolysin has decades of use in Eastern European and Asian markets; Semax is registered as a pharmaceutical in Russia. None are FDA-approved in the United States.

Melanocortin and reproductive peptides. PT-141 (bremelanotide) is FDA-approved for acquired generalized hypoactive sexual desire disorder in premenopausal women under the brand name Vyleesi. Melanotan-2 is an unapproved analogue. Kisspeptin research has produced both mechanistic insight and therapeutic candidates.

Thymic and immune peptides. Thymosin alpha-1 is approved in multiple countries outside the United States as Zadaxin for specific immune and oncologic indications.

Mitochondrial peptides. SS-31 (elamipretide), MOTS-c, Humanin. These target mitochondrial function through distinct mechanisms. Elamipretide has been evaluated in multiple clinical trials.

This taxonomy is not exhaustive, and compounds often sit at the boundaries of categories. The TriedRx peptide profile library at /peptides/ maintains individual entries for the peptides most frequently discussed in the literature.

4. Research Use Versus Approved Use

In short: "FDA approved" means a regulator has reviewed human trial data and said yes. "Research chemical" means the compound is being sold under labeling that says it's not for human use — a regulatory category, not a quality judgment. The single most important conceptual distinction for a new reader is the difference between a peptide that has a regulatory approval and a peptide that is sold as a research chemical. Approval means a regulatory agency (the FDA in the United States, the EMA in the European Union, the MHRA in the United Kingdom, the TGA in Australia) has reviewed controlled trials demonstrating safety and efficacy for a specific indication and issued a marketing authorization for that indication. The short list of peptides with current FDA approval as of the 2026 writing of this guide includes semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide, tesamorelin, bremelanotide, and a small number of others, each for a narrowly defined indication [1,2,5].

Research-chemical peptides are sold under a labeling convention that declares the product is not for human consumption and is intended for in vitro research only. This labeling exists because the compounds lack regulatory approval. Purchasing or possessing these compounds in many jurisdictions is not itself illegal, but selling them for human use generally is. The compounded-pharmacy channel, which has produced substantial volumes of semaglutide, tirzepatide, and BPC-157 in the United States, operates under a separate regulatory framework documented in the TriedRx guides on 503A compounding pharmacy and 503B compounding pharmacy.

5. Legal Status by Jurisdiction

In short: a peptide can be legal to possess, illegal to sell for human use, and banned in competition — all at the same time. The three rule sets don't overlap cleanly. Peptide legality is complicated by three overlapping regulatory axes: drug-law classification, athletic-doping rules, and import rules. A compound can be legal to possess, illegal to sell for human use, and prohibited in competition simultaneously.

United States. Possession of most research peptides is not a federal crime in the absence of intent to distribute for human consumption. Sale for human use generally requires a new drug application, abbreviated new drug application, or compounding under Section 503A or 503B of the Food, Drug, and Cosmetic Act. In 2023 and 2024, the FDA issued guidance removing BPC-157, CJC-1295, ipamorelin, and several other peptides from the 503A bulks list, meaning they can no longer be compounded by typical compounding pharmacies. Semaglutide and tirzepatide remain available through 503A compounding only during FDA-declared drug shortages. See /guides/are-peptides-legal for the current regulatory map.

European Union and United Kingdom. Marketing authorization through the EMA (EU) or MHRA (UK) is required for human therapeutic use. Research-chemical import rules vary by member state. The UK's Medicines and Healthcare products Regulatory Agency enforces stringent restrictions on supply without authorization.

Australia. The Therapeutic Goods Administration (TGA) classifies most peptides without marketing authorization as Schedule 4 (prescription only) at minimum; some fall under Schedule 10. Importation is governed by the Personal Importation Scheme and its exceptions.

Canada. Health Canada regulates peptide therapeutics under the Food and Drugs Act. Most research peptides lack Drug Identification Numbers and cannot be legally sold for human use.

Readers should not rely on this summary as legal advice. Jurisdictional rules change, and athletic bodies (WADA and affiliated national agencies) maintain separate prohibited-substance lists that update annually.

6. Why People Use Peptides in the Research Literature

In short: the formal literature studies peptides for specific disease indications (diabetes, obesity, lipodystrophy, ulcers). Community use extends well beyond those indications, which is why both sets of data matter. The primary literature documents a distinct set of motivations for studying each peptide class. GLP-1 agonists are studied for metabolic disease, obesity, cardiovascular protection, and emerging indications in addiction and neurodegeneration [1,2]. GH secretagogues are studied for age-related sarcopenia, HIV-associated lipodystrophy (the tesamorelin indication), pediatric growth deficiency in some cases, and body composition endpoints [5]. Healing peptides are studied for tendon and ligament repair, gastric ulcer models, and inflammatory bowel disease [6]. Mitochondrial peptides are studied for primary mitochondrial disease, ischemia-reperfusion injury, and heart failure.

Outside the formal literature, community self-report data describe a wider range of reasons for peptide use that include aesthetic, recreational, and biohacking motivations. TriedRx treats community self-report data as a data source worth documenting, with explicit labeling, because ignoring it would leave readers at the mercy of the vendor narrative that targets those use cases. Community data is not evidence of efficacy; it is evidence of use patterns.

7. How to Read the Primary Literature (PubMed Walkthrough)

In short: PubMed is the free, public database of biomedical research. Search by generic name, filter by publication type, and follow citation chains back to foundational papers. The PubMed database at pubmed.ncbi.nlm.nih.gov is the canonical starting point for peptide research. A first-time reader should practice the following routine.

Start with the generic name of the peptide, not the brand name. Searching "semaglutide" returns a broader literature set than "Ozempic." Apply filters for publication type: review articles summarize larger bodies of work; clinical trial filters narrow to human studies; systematic reviews and meta-analyses aggregate evidence quantitatively. The "Best Match" sort often surfaces foundational or highly cited work first.

Read abstracts critically. The four structured sections (background, methods, results, conclusions) often disclose the study's limitations more honestly than the discussion section of the full paper. Note whether the subjects are rodents, cell lines, or humans. Note whether the sample size is small enough that the findings must be considered preliminary. Note whether the effect sizes are clinically meaningful or merely statistically significant.

Check for registered trials at ClinicalTrials.gov. A peptide with zero registered human trials is still in the preclinical stage regardless of what the vendor marketing suggests. A peptide with multiple completed phase 2 or phase 3 trials has a different evidence base, and the trial registry is where that evidence lives before it is fully published.

Beware review articles authored by a single research group. Peptides with literature dominated by a single laboratory carry a replication risk that independent readers may not notice until the field as a whole begins asking for external validation. This is a recurring issue for several tissue-repair peptides.

Be willing to follow citation chains backward. The first citation in a review article is often the foundational paper that established the peptide's sequence, synthesis, or initial biological activity. That primary source usually contains more useful information than downstream summaries.

8. Red Flags in Vendor Marketing

In short: vendor pages are sales copy. Treat therapeutic claims, before-and-after photos, and vague "pharmaceutical grade" language as marketing — not evidence. Vendor content is designed to sell product. The TriedRx editorial standard treats vendor claims as marketing, not evidence. The following signals typically indicate that a vendor is writing to convince rather than inform.

Therapeutic efficacy claims for non-approved peptides. If a product page tells the reader that BPC-157 "heals tendons," that is a clinical claim for an unapproved compound, and it is both legally problematic for the vendor and epistemically unsupported by human data. Careful vendors use research-context language ("has demonstrated tissue-repair activity in animal models") or decline to make claims at all.

Before-and-after imagery or testimonials framed as representative outcomes. These are anecdotes, not evidence, and regulators in multiple jurisdictions have cited vendors for this practice.

Absence of certificates of analysis, or generic certificates that do not match the batch being sold. Third-party lab testing is the only way to verify peptide purity and identity, and sophisticated vendors publish batch-specific certificates that match lot numbers visible on the product.

Claims of "pharmaceutical grade" without documentation of USP or compendial-grade sourcing. Grade language is freely used and rarely substantiated.

Discount codes bundled with dosing instructions. A vendor who sells the product and then teaches the reader how to use it is operating outside the research-chemical framing that notionally permits sale of the compound.

Claims of stability data without citation. Peptide stability after reconstitution varies substantially by compound and storage conditions, and any generic stability claim that isn't tied to specific published work should be regarded as marketing.

Claims of proprietary blends without identity verification. A reader buying a "recovery blend" without a certificate of analysis for each component is buying a mystery. Labs that test blends frequently report deviations from the stated ratios or absence of components entirely.

9. How TriedRx Ranks Vendors

In short: TriedRx aggregates publicly available third-party lab reports, transparency disclosures, and reputation data — then grades vendors on a transparent rubric. We don't run our own lab. TriedRx operates an independent vendor rating program built around reviewing publicly available third-party lab reports (COAs and HPLC/MS data vendors publish), transparency signals (whether they disclose a licensed pharmacist, lot traceability, testing cadence), reputation signals, and operational data. We describe the full methodology in the Editorial Policy and do not accept payments, affiliate commissions, or sponsored content. Readers evaluating vendors can use the rankings as an independent data layer that sits alongside (not inside) vendor-produced marketing content. See the brands directory for the full list of vendors we have rated to date.

The rubric weighs lab-data quality (HPLC purity percentages, mass-spec identity confirmation, water content by Karl Fischer, endotoxin data where published), lot traceability, accreditation of the testing laboratory, reporting cadence, and the quality of the paperwork a vendor actually produces. A high rating is not a statement that the peptide is safe for human use; it is a statement that the vendor's published quality and transparency data, as we compiled it, meets the rubric at a specified level. Vendor failures and missing data are published with the same prominence as strong scores.

10. Reading Evidence Grades in Peptide Research

In short: approved-indication peptides have the strongest evidence. "Animal studies only" peptides are still at the hypothesis stage when it comes to human benefit. The TriedRx peptide library attaches an evidence grade to each profile. Readers encountering peptides for the first time should understand what these grades mean in practice. An approved-indication grade signals that a peptide has been reviewed by a regulator and is available on prescription for a defined condition; semaglutide, liraglutide, tirzepatide, tesamorelin, and bremelanotide sit in this tier for their respective indications. A human-clinical-trial grade signals that the compound has completed or is actively enrolling controlled human studies without yet reaching approval; retatrutide and elamipretide sit here. An animal-studies grade signals that the published evidence is preclinical, and human translation remains conjectural; BPC-157, TB-500, and most bioregulators sit here. A mechanistic-only grade signals that the compound has been characterized in vitro or in narrow animal systems without body-system evidence of efficacy.

Evidence grades are editorial judgments summarizing the strength and breadth of the literature at the time of writing. They are not predictions that a lower-graded compound will fail in future human trials, nor endorsements that a higher-graded compound is safe for any individual reader.

11. Common Peptide Misconceptions a New Reader Should Avoid

In short: "your body makes it," "pharmaceutical grade," "peer-reviewed," and "research-only labeling" are phrases that sound authoritative but often mean less than readers assume. Several claims recur frequently in peptide community content and deserve direct correction.

"Your body makes it, so it must be safe." The endogenous presence of a peptide or peptide fragment does not imply that exogenous administration at supraphysiologic doses is safe. Endogenous insulin is essential to life; exogenous insulin taken without indication is lethal. The same logical frame applies to peptides that have endogenous analogues.

"Pharmaceutical-grade means human-use quality." The phrase "pharmaceutical grade" is not a defined regulatory term. The defined terms are USP grade, EP grade, JP grade (US, European, Japanese Pharmacopeia), and Good Manufacturing Practice (GMP) certification at specified levels. Vendors using "pharmaceutical grade" language without compendial or GMP documentation are using marketing vocabulary.

"Peer-reviewed means correct." Peer review is a quality filter, not a truth filter. The majority of published biomedical findings do not replicate cleanly. A single paper, even a well-cited one, is not a proof. Aggregated evidence across laboratories, study designs, and populations is the correct reference standard.

"GRAS or supplement status covers peptides." Generally Recognized As Safe is a food-ingredient classification. Peptides sold as dietary supplements are regulated under the Dietary Supplement Health and Education Act and have specific structure-function rules; most peptides currently discussed in the research-chemical market do not qualify as dietary supplements, and marketing them as such invites regulatory action.

"Research-only labeling protects the buyer." The research-use-only label is a marketing convention documenting the seller's position. It does not transform the compound's regulatory status, does not guarantee identity or purity, and does not establish that a human can safely consume the material.

12. Where to Go Next in Peptide Research

In short: start with the operational guides (reconstitution, storage, syringes), then dive into individual peptide profiles for the compounds you're researching. Readers new to the category typically benefit from reading, in order, the peptide reconstitution guide, the peptide storage and handling guide, and the peptide syringe measurement guide. The glossary and FAQ answer narrower questions. Individual peptide profiles such as BPC-157, semaglutide, and tirzepatide link to the dosing reference pages for those specific compounds. Readers specifically comparing the approved GLP-1 family should start with semaglutide vs. tirzepatide and retatrutide vs. tirzepatide. Readers orienting to regulatory status should pair this guide with Are peptides legal and the two compounding-pharmacy explainers linked above.

References

1. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. PMID: 34626851.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
3. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. PMID: 28720325.
4. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. DOI: 10.1021/ja00897a025.
5. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338.
6. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887.
7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Center for Drug Evaluation and Research; updated 2024.